Opioids Can't Stop Califf Confirmation
This article was originally published in The Pink Sheet Daily
Commissioner nominee draws overwhelming Senate support – but also bipartisan opposition to FDA's policy on pain products.
You may also be interested in...
Advisory committees will discuss whether data from a 41-patient study should be added to Pediatric Use section of labeling for Purdue's buprenorphine product; agency's decision to convene expert panel even though a pediatric indication is not being considered grew out of criticism generated by approval of OxyContin for adolescents.
US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.
US FDA met with a group concerned about seafood consumption advice for pregnant and nursing women; could it satisfy Sen. Murkowski and avoid a hold on Scott Gottlieb's nomination?